Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Open Clinical Research Studies

Studies are currently being conducted locally in the following specialty areas, with more specialty studies planned in the future.

Cardiovascular Studies

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 9REGN727) (ODYSSEY Outcomes)
Principal Investigator: William R. Herzog, M.D.
Learn More
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP (CANTOS)
Principal Investigator: William R. Herzog, M.D.
Learn More
Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE).
Principal Investigator: William R. Herzog, M.D.
Learn More
Protocol I1V-MC-EIAN. Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes –  (ACCELERATE )
Principal Investigator: William R. Herzog, M.D.
Learn More
A prospective, open label study evaluating the efficacy of two management strategies (pantoprazole 40 mg q.a.m. and taking Pradaxa® with food (within 30 minutes after a meal)) on gastrointestinal symptoms (GIS) in patients newly on treatment with Pradaxa® 150 mg b.i.d., 110 mg b.i.d. or 75 mg b.i.d. for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)
Principal Investigator: William R. Herzog, M.D.
Learn More
D5135C00001: A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID)
Principal Investigator: William R. Herzog, M.D.
Learn More
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease. AMG 145 (FOURIER)
Principal Investigator: William R. Herzog, M.D.
Learn More
A Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of AMG 145 Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization (GLAGOV)
Principal Investigator: William R. Herzog, M.D.
Learn More
Dapagliflozin Effect on CardiovascuLAR Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients  with Type 2 Diabetes (DECLARE)
Principal Investigator: William R. Herzog, M.D.
Learn More
 

Having a Baby?

Having a Baby Learn everything you need to know about having your baby at HCGH and view a virtual tour.
 

Preparing for Surgery

Learn what to expect, where to go, and how to prepare for a surgical procedure at HCGH. 
 

Servicios en Español

Una guía en español a todos los servicios que HCGH brinda para mejorar la salud de toda nuestra communidad.
 

Make a Gift

Make a Gift

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer